We will quote to you most important and trendy news about all kind of Vaccine of the best health sites Like : "zmescience" and the most famous medical experts : Mihai Andrei
daily : 2016-12-12 & on time : 7:29
according to
Revolutionary HIV vaccine to be tested on 600 people next year
image uploaded by "zmescience" site
HIV is still one of the most devastating diseases in human history, with 36.7 million people being infected in 2015 – including 1.8 million children.But scientists are not slumbering, and for decades they have been working on ways to attack the disease.Now, we may be zooming in on a working vaccine, as human tests are set to start next year.
about the details read more from here
A first-of-its-kind HIV vaccine will move to phase II trials in 2017
image uploaded by "sciencealert" site
A brand new type of HIV vaccine will move onto phase II clinical trials in 2017, after phase I trials showed that it was safe to use in humans.The potential new vaccine will be tested on 600 people in North America, to see how well it can prevent them from getting the virus.Before we get too excited, the phase I trials were only set up to show that the vaccine was tolerated well by the human body - they didn't demonstrate if it actually works as a preventative treatment.
about the details read more from here
New HIV vaccine strategy targets body's mucosal sites
image uploaded by "scidev" site
"Our vaccine approach aims at making the antibodies inhibit the HIV Tat (Transactivator of HIV gene expression) effect, thereby preventing the HIV virus from replicating." Eric Gowans, University of Adelaide[SYDNEY] A recombinant rhinovirus (common cold virus) used along with an injection of DNA-based vaccine can activate the immune system against transmission of human immunodeficiency virus (HIV) via mucosal sites, say researchers in Australia.Results from a mouse model trial may help develop effective mucosal HIV-1 vaccines in the future.Unlike previous vaccine trials, the new approach offers protection at mucosal sites — vaginal or rectal — that are most likely to encounter the virus first.Eric Gowans, who is leading the research team at the University of Adelaide's Basil Hetzel Institute for Translational Health Research , says, "Our vaccine approach aims at making the antibodies inhibit the HIV Tat (Transactivator of HIV gene expression) effect, thereby preventing the HIV virus from replicating.We believe that our strategy may be more effective than other studies for three reasons: Our vaccine will elicit mucosal immunity to Gag (The capsid proteins or group specific antigens) and Tat; systemic immunity to Tat; and cell-mediated immunity to Gag and Tat."Approximately 80 per cent of HIV infections are the result of mucosal transmission.
about the details read more from here
No comments:
Post a Comment